Related references
Note: Only part of the references are listed.Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer The REALITY Randomized Clinical Trial
Yansong Lin et al.
JAMA ONCOLOGY (2022)
Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan
Chen-Yuan Lin et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2021)
Prognostic Impact of Histologic Grade for Papillary Thyroid Carcinoma
Allen S. Ho et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Current practice in patients with differentiated thyroid cancer
Martin Schlumberger et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Dong Ding et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states
Feng Wen et al.
LIVER INTERNATIONAL (2021)
Burden of Thyroid Cancer From 1990 to 2019 and Projections of Incidence and Mortality Until 2039 in China: Findings From Global Burden of Disease Study
Fang Cheng et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
Qilin Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
Xiangqian Zheng et al.
CLINICAL CANCER RESEARCH (2021)
Pre-Therapeutic Measurements of Iodine Avidity in Papillary and Poorly Differentiated Thyroid Cancer Reveal Associations with Thyroglobulin Expression, Histological Variants and Ki-67 Index
Joachim N. Nilsson et al.
CANCERS (2021)
Global Burden of Thyroid Cancer From 1990 to 2017
YuJiao Deng et al.
JAMA NETWORK OPEN (2020)
Understanding the ever-changing incidence of thyroid cancer
Cari M. Kitahara et al.
NATURE REVIEWS ENDOCRINOLOGY (2020)
Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial
Wenxiu Xin et al.
BMJ OPEN (2020)
Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Jiangping Yang et al.
FRONTIERS IN ONCOLOGY (2020)
First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis
Yingjie Su et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Masahiro Kobayashi et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China
Haijing Guan et al.
CLINICAL THERAPEUTICS (2019)
The real world and thinking of thyroid cancer in China
Lin Han et al.
INTERNATIONAL JOURNAL OF SURGERY-ONCOLOGY (2019)
Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma
S. de Groot et al.
QUALITY OF LIFE RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer
Hong-Dou Chen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer
Vincenzo Marotta et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Leslie Wilson et al.
THYROID (2017)
Mutated BRAF and personalised medicine in differentiated thyroid cancer
Keith C. Bible et al.
LANCET ONCOLOGY (2016)
The changing incidence of thyroid cancer
Cari M. Kitahara et al.
NATURE REVIEWS ENDOCRINOLOGY (2016)
COST-EFFECTIVENESS ANALYSIS OF LENVATINIB AS A TREATMENT FOR RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE UNITED STATES
G. Tremblay et al.
VALUE IN HEALTH (2016)
THE EVPI OF TREATMENT STRATEGIES FOR RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
W. Huang et al.
VALUE IN HEALTH (2016)
Initial attributable cost and economic burden of clinically-relevant differentiated thyroid cancer: A health care service provider perspective
B. H. -H. Lang et al.
EJSO (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer
Beth A. Fordham et al.
PATIENT PREFERENCE AND ADHERENCE (2015)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Life Expectancy Is Reduced in Differentiated Thyroid Cancer Patients >= 45 Years Old with Extensive Local Tumor Invasion, Lateral Lymph Node, or Distant Metastases at Diagnosis and Normal in All Other DTC Patients
Frederik A. Verburg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy
Fernanda Vaisman et al.
CLINICAL ENDOCRINOLOGY (2012)
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients
Maria Grazia Castagna et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Long-Term Follow-Up of Patients with Papillary and Follicular Thyroid Cancer: A Prospective Study on 715 Patients
M. Brassard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer
A. Piccardo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2010)
Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System
R. Michael Tuttle et al.
THYROID (2010)
Share Paper
